John Higuchi Biography and Net Worth

Director of Lipocine

John W. Higuchi, M.B.A. has served as a member of our Board of Directors since 2003. Mr. Higuchi served as Chief Executive Officer of Aciont Inc., an ocular therapeutics company in Utah from 2003 to 2022. Mr. Higuchi also is a co-founder and serves on the Board of Directors of Spriaso, LLC, a specialty pharmaceutical company in Utah. From 1997 to 2003, Mr. Higuchi served as our Vice President of Business Development and Corporate Treasurer. Mr. Higuchi received a B.S. in Chemistry from Hope College and an M.B.A. and M.S. in Information Systems from The George Washington University. We believe that Mr. Higuchi’s business development and management experience in the therapeutics industry, together with his significant knowledge of our Company obtained while serving as a director of our Company, greatly benefits our Board of Directors.

What is John W. Higuchi's net worth?: The estimated net worth of John W. Higuchi is at least $473.33 thousand as of September 29th, 2026. Mr. Higuchi owns 225,395 shares of Lipocine stock worth more than $473,330 as of October 2nd. This net worth estimate does not reflect any other investments that Mr. Higuchi may own. Learn More about John W. Higuchi's net worth.
How do I contact John W. Higuchi?: The corporate mailing address for Mr. Higuchi and other Lipocine executives is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. Lipocine can also be reached via phone at (801) 994-7383 and via email at [email protected]. Learn More on John W. Higuchi's contact information.
Has John W. Higuchi been buying or selling shares of Lipocine?: John W. Higuchi has not been actively trading shares of Lipocine over the course of the past ninety days. Most recently, on Wednesday, September 30th, John W. Higuchi bought 15,970 shares of Lipocine stock. The stock was acquired at an average cost of $2.23 per share, with a total value of $35,613.10. Following the completion of the transaction, the director now directly owns 241,365 shares of the company's stock, valued at $538,243.95. Learn More on John W. Higuchi's trading history.
Who are Lipocine's active insiders?: Lipocine's insider roster includes John Higuchi (Director), and Mahesh Patel (CEO). Learn More on Lipocine's active insiders.
Are insiders buying or selling shares of Lipocine?: In the last year, Lipocine insiders bought shares 7 times. They purchased a total of 250,568 shares worth more than $516,774.41. The most recent insider tranaction occured on September, 30th when Director John W. Higuchi bought 15,970 shares worth more than $35,613.10. Insiders at Lipocine own 4.7% of the company. Learn More about insider trades at Lipocine.
Information on this page was last updated on 9/30/2026.

John W. Higuchi Insider Trading History at Lipocine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/30/2026	Buy	15,970	$2.23	$35,613.10	241,365
9/29/2026	Buy	9,037	$2.15	$19,429.55	225,395
9/28/2026	Buy	12,561	$2.16	$27,131.76	216,358
4/7/2026	Buy	40,000	$2.03	$81,200.00	203,797
4/6/2026	Buy	123,000	$2.05	$252,150.00	163,797
12/31/2020	Sell	394	$22.95	$9,042.30
3/17/2020	Buy	12,941	$5.44	$70,399.04
9/30/2015	Buy	294	$215.56	$63,374.64	40,787

John W. Higuchi Buying and Selling Activity at Lipocine

Lipocine Company Overview

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $2.08

$2.08

$2.13

50 Day Range

MA: $2.17

$2.04

$2.45

2 Week Range

Now: $2.08

$1.81

$12.37

Volume

25,674 shs

Average Volume

186,046 shs

Market Capitalization

$17.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4